Loew F, Pawlak C, Benaroyo L, Junod J P
Geriatric Hospital, University Institutions of Geriatrics, Department of Medicine, Geneva, Switzerland.
Arzneimittelforschung. 1988 Apr;38(4):563-7.
The efficacy and safety of 15 mg midazolam versus 15 mg oxazepam were compared in a double-blind clinical trial in 61 aged hospitalized patients (mean age 82.5, range 69 to 96), suffering from moderate to severe insomnia. The study covered 8 nights, i.e., 1 placebo night followed by 5 treatment nights and 2 further placebo nights. Both drugs were equally effective with respect to total sleep time, number of nocturnal awakenings, quality of sleep, condition on awakening, patients' assessment and dreams. However, sleep latency was significantly shorter in the midazolam group, which was also rated significantly more favorably by the medical staff. Side effects were mild and similar in both groups. No rebound or carry-over effects were noted. Midazolam can be considered an effective and safe sleep inducer in aged patients.
在一项双盲临床试验中，对61名年龄较大的住院患者（平均年龄82.5岁，范围69至96岁）进行了比较，这些患者患有中度至重度失眠，比较了15毫克咪达唑仑与15毫克奥沙西泮的疗效和安全性。该研究涵盖8个晚上，即1个安慰剂夜，随后是5个治疗夜和另外2个安慰剂夜。在总睡眠时间、夜间觉醒次数、睡眠质量、醒来时的状况、患者评估和梦境方面，两种药物同样有效。然而，咪达唑仑组的睡眠潜伏期明显更短，医务人员对该组的评价也明显更高。两组的副作用均较轻且相似。未观察到反跳或残留效应。咪达唑仑可被认为是老年患者有效的安全睡眠诱导剂。
